Trade Vir Biotechnology VIR

VirBiotechnology live chart

Mga Pangunahing Kaalaman sa Instrumento

Weekly Search
Weekly
Daily
Petsa Isarado Pagbabago Change (%) Buksan High Low

VirBiotechnology news

Mga pinakabagong balita

Ipakita nang marami
Noah Lee 2025 Sep 15, 15:20

Gold Rush in the Trump Era: Investors Seek Haven Amid Uncertainty

Noah Lee 2025 Sep 15, 13:20

Musk's Tesla Stock Purchase Fuels Confidence, Sends Shares Soaring

Liam James 2025 Sep 15, 13:20

Trump Proposes Semiannual Reporting for US Companies: Cost Savings or Reduced Transparency?

Ava Grace 2025 Sep 15, 12:20

Russia Tests Zircon Missile, Drills with Belarus; US Observes Amid Geopolitical Maneuvering

Ava Grace 2025 Sep 15, 11:20

Fed Rate Hike Outlook 2025: Inflation and Jobs Market in Focus

Emma Rose 2025 Sep 15, 10:20

India Gold Demand Forecast to Weaken During Festival Season Due to High Prices

Noah Lee 2025 Sep 15, 09:20

Fed Rate Cut Outlook Amid Sticky Inflation and Labor Market Signals

Emma Rose 2025 Sep 15, 09:20

US Job Market Slowdown: Trade Turmoil's Impact and Future Outlook

Info

Spread

0.03

Spread (%)

0.6237 %

Leverage

1:10

Interes sa Magdamagang Pagbili

-0.0597 %

Interes sa Magdamagang Pagtinda

-0.0292 %

Currency

USD

Trading Hours

Oras ng Pagbubukas

Lunes

13:31 - 19:59

Martes

13:31-19:59

Miyerkules

13:31-19:59

Huwebes

13:31-19:59

Biyernes

13:31-19:59

Analys och statistik

Buksan

---

Nakaraang Pagsara

---

52 Linggo Mataas/Mababa

--- – ---

Market Cap

694579968

Natitirang Pagbabahagi

138916000

Petsa ng Mga Kita (Susunod)

0000-00-00

Pambayad si dividend

Araw ng Pag-alis ng Karapatan sa Dividend

Inaasahang Taunang Rate ng Dividend

0

Inaasahang Taunang Dividend Yield

0

EPS

-4.01

Alamin ang Higit Pa Tungkol sa Instrumentong ito

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Mga kaugnay na instrumento

view_all_instruments

latest_education_articles

Ipakita nang marami
Trustpilot